Xenetic Biosciences, Inc.
XBIO · XNASCIK 1534525fmd_1KJYGBZSMHNN8GQBVMB5F9ES4WManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Dec 01, 2010 to Sep 30, 2026, 65 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 3 | 8 | 0 | 0 | 0 | 1 | 2 | 3 | 3 | 3 |
| Cost of revenue | – | – | – | – | – | – | – | – | – | – |
| Net interest income | – | (0) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | – | – | – | – | – | – | – | – | – | – |
| Research and development | 44 | 4 | 3 | 5 | 2 | 3 | 5 | 3 | 3 | 3 |
| Total operating expenses | – | – | 7 | 13 | 14 | 7 | 8 | 7 | 7 | 6 |
| Operating income | (47) | (4) | (7) | (13) | (14) | (6) | (7) | (5) | (4) | (3) |
| Interest expense | 1 | 0 | – | – | – | – | – | – | – | – |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (7) | (0) | (0) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before taxes | – | – | – | – | – | – | – | – | – | – |
| Income tax expense | 0 | 0 | 0 | 0 | (3) | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | – | – | – | – | – |
| Net income | (54) | (4) | (7) | (13) | (11) | (6) | (7) | (4) | (4) | (3) |
| Net income to common shareholders | (58) | (4) | (7) | (18) | (11) | – | – | – | – | – |